Cholangiocarcinoma Archives

Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

Post author:Jessica Lynn
Post published:February 8, 2024
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Source: pixabay.com

NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:September 11, 2023
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

In the United States, the FDA grants Orphan Drug designation to drugs or biologics that are intended to treat, diagnose, or prevent rare conditions. A rare condition is one…

source: shutterstock.com

Do Cross-Over Arms in Clinical Oncology Trials Benefit Patients?

Post author:James Moore
Post published:August 21, 2023
Post category:Cholangiocarcinoma

The Cholangiocarcinoma Foundation has recently released a white paper titled “Cross-over arms in oncology clinical trials: An important consideration for patients.” This paper highlights a non-traditional clinical trial approach that…

skeeze / Pixabay

Zanidatamab Could Treat HER2 Mutated Bile Duct Cancer

Post author:Jessica Lynn
Post published:June 21, 2023
Post category:Bile duct cancer Cholangiocarcinoma

Zanidatamab is an investigational IgG1 bi-specific monoclonal antibody that targets two non-overlapping HER2 domains. HER2 is overexpressed in a variety of cancer types such as breast cancer and esophageal cancer.…

source: pixabay.com

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

Post author:Rose Duesterwald
Post published:May 23, 2023
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

For patients who were given a diagnosis of advanced, inoperable (unresectable) biliary tract cancer, an article appeared in Healio with some encouraging news. Gemcitabine and cisplatin drugs have…

source: pixabay.com

ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:December 19, 2022
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Rare diseases are, by their nature, rare—and because of this, it can be difficult to spur drug development. The FDA worked to overcome this through the creation of the…

source: unsplash.com

GNS561 Earns Orphan Drug Designation for Cholangiocarcinoma

Post author:Jessica Lynn
Post published:September 28, 2022
Post category:Cholangiocarcinoma

According to an article from Cancer Network, the U.S. Food and Drug Administration (FDA) recently granted Orphan Drug designation to second-line GNS561 (ezurpimtrostrat) for cholangiocarcinoma (bile duct cancer). In…

source: pixabay.com

Devimistat for Biliary Tract Cancer Earns EMA Orphan Drug Designation

Post author:Jessica Lynn
Post published:May 26, 2022
Post category:Biliary tract cancer Cholangiocarcinoma

In Europe, Orphan Drug designation is granted to therapies intended to treat, prevent, or diagnose a rare, life-threatening, or debilitating disease. For the purpose of this status, rare conditions…

source: pixabay.com

Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

Post author:James Moore
Post published:April 18, 2022
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Nelson Ambrogio had always looked up to his older brother, Daniel. He has many positive memories of growing up with him. They both shared a passion for soccer, and Nelson…

source: pixabay.com

ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer

Post author:Jessica Lynn
Post published:March 15, 2022
Post category:Biliary tract cancer Cholangiocarcinoma

In late February 2022, biopharmaceutical company Trascenta Holding Limited ("Trascenta") provided an update on its clinical program for TST001, a monoclonal antibody therapy designed for those with locally advanced or…

jarmoluk / Pixabay

Adding Durvalumab to Chemotherapy Extends Survival in Patients with Advanced Biliary Tract Cancer

Post author:Alyssa Stevens
Post published:March 2, 2022
Post category:Biliary tract cancer Cholangiocarcinoma

According to a recent article, researchers have found that adding durvalumab to chemotherapy treatments results in prolonged survival rates in patients with advanced biliary tract cancer. Biliary Tract Cancer Biliary…

source: pixabay.com

Ruth Stage, Inc. is Fundraising for the Cholangiocarcinoma Foundation

Post author:Kendall Mason
Post published:September 28, 2021
Post category:Cholangiocarcinoma

Funding is a problem that many rare diseases face when it comes to research. Cholangiocarcinoma, also known as bile duct cancer, is no exception. Because of this, it is often…

New Diagnostic Tool For Cholangiocarcinoma is FDA Approved

Post author:Trudy Horsting
Post published:September 23, 2021
Post category:Cholangiocarcinoma

The FDA has recently approved a new diagnostic tool to help determine which IDH1-mutated cholangiocarcinoma patients may be a good fit for the novel IDH1 inhibitor called ivosidenib. The new…

Advanced Cholangiocarcinoma Treatment Infigratinib Granted Accelerated Approval by FDA

Post author:Alyssa Stevens
Post published:September 16, 2021
Post category:Cholangiocarcinoma

According to a recent article at Pharmacy Times, Infigratinib has been granted accelerated approval for the treatment of those with metastatic cholangiocarcinoma. The treatment is for adults whose cholangiocarcinoma is…

source: pixabay.com

Phase 3 Global Trial for Cholangiocarcinoma Testing a Single Agent is Well Underway

Post author:Trudy Horsting
Post published:July 30, 2021
Post category:Bile duct cancer Cholangiocarcinoma

Updates from the Phase 3 clinical trial called FIGHT-302 were just released at the 2021 European Society for Medical Oncology World Congress on Gastrointestinal Cancer. The trial is comparing two…

source: pixabay.com

Survey Finds Cholangiocarcinoma Oncologists Could Improve Patient Care by Collaborating with Pharmacists

Post author:Trudy Horsting
Post published:July 29, 2021
Post category:Cholangiocarcinoma

A survey of oncologists has found that more education is clearly needed regarding cholangiocarcinoma. Specifically, more education would be beneficial regarding testing and targeting the mutations which cause the condition…

source: pixabay.com

Devimistat for Biliary Cancer Granted Orphan Drug Status

Post author:Jessica Lynn
Post published:July 9, 2021
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

According to MPR, the FDA recently granted Orphan Drug designation to CPI-613 (devimistat), an investigational treatment designed for patients with biliary cancer. Altogether, "biliary cancer" can consist of bile…

source: pixabay.com

The Second Ever FDA Approved Drug for Cholangiocarcinoma (CCA)

Post author:Sunniva Bean
Post published:July 6, 2021
Post category:Bile duct cancer Cholangiocarcinoma

As reported in Fierce Pharma; BridgeBio has earned FDA approval for their new targeted cancer treatment, Truseltiq. The approval is the biotech company’s first ever approval for a cancer drug,…

source: pixabay.com

NORD Interactive Virtual Forum: Working While Rare

Post author:James Moore
Post published:July 2, 2021
Post category:Cholangiocarcinoma Ehlers-Danlos Syndrome Rare Disease

Patient Worthy was a media partner at this year's NORD Living Rare, Living Stronger Patient and Family Forum. This is an annual event hosted by the National Organization for Rare…

stevepb / Pixabay

Truseltiq Approved for Metastatic Cholangiocarcinoma

Post author:Jessica Lynn
Post published:June 21, 2021
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

In late May 2021, the FDA granted accelerated approval to Truseltiq (infigratinib). As reported by Cure, this therapy is designed for adult patients with unresectable locally advanced, previously treated, or…

Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

Do Cross-Over Arms in Clinical Oncology Trials Benefit Patients?

Zanidatamab Could Treat HER2 Mutated Bile Duct Cancer

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

GNS561 Earns Orphan Drug Designation for Cholangiocarcinoma

Devimistat for Biliary Tract Cancer Earns EMA Orphan Drug Designation

Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer

Adding Durvalumab to Chemotherapy Extends Survival in Patients with Advanced Biliary Tract Cancer

Ruth Stage, Inc. is Fundraising for the Cholangiocarcinoma Foundation

New Diagnostic Tool For Cholangiocarcinoma is FDA Approved

Advanced Cholangiocarcinoma Treatment Infigratinib Granted Accelerated Approval by FDA

Phase 3 Global Trial for Cholangiocarcinoma Testing a Single Agent is Well Underway

Survey Finds Cholangiocarcinoma Oncologists Could Improve Patient Care by Collaborating with Pharmacists

Devimistat for Biliary Cancer Granted Orphan Drug Status

The Second Ever FDA Approved Drug for Cholangiocarcinoma (CCA)

NORD Interactive Virtual Forum: Working While Rare

Truseltiq Approved for Metastatic Cholangiocarcinoma

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More